ArticleCurrent microbiology2025
Antimicrobial Efficacy of Cloxacillin-Loaded Chitosan Nanoparticles Against Staphylococcus aureus Biofilms in Subclinical Mastitis.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bovine Mastitis Therapy at a Crossroads: Pharmacokinetic Barriers, Biofilms, Antimicrobial Resistance, and Emerging Solutions.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Chitosan nanoparticles as a sustainable antibacterial approach for inhibitingOpen veterinary journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine mastitis is the most widespread disease that causes financial loss in the dairy industry. Staphylococcus aureus is a well-researched multidrug-resistant opportunistic bacterium that is frequently linked to subclinical mastitis and causes significant economic losses. A further problem in the management of S. aureus infections is its capacity to form biofilms; bacteria inside biofilms exhibit greater resistance to antimicrobials than planktonic cells. The most effective method for controlling mastitis is antibiotic therapy. Cloxacillin (CLX), ampicillin, and ceftiofur are currently the most often utilized drying treatments for dairy cattle. We have evaluated the therapy efficiency of cloxacillin-loaded chitosan nanoparticles (CLX-CS NPs) as well as the relationship between biofilm production, gene profile and the type of trial group (CLX and CLX-CS NPs) against S.aureus isolated from milk samples of cows diagnosed with subclinical mastitis. Investigation of phenotypic biofilm production showed that majority of the S. aureus isolates extracted from milk were producers of biofilm. Cloxacillin-loaded chitosan nanoparticles were able to significantly decrease the MIC (p < 0.05) and MBC values compared to cloxacillin. The relationship between the gene profile and the types of trial groups shows that coating cloxacillin with chitosan nanoparticles (CS-NPs) was able to reduce the MIC and MBC value in all nine gene profile groups. These findings indicate that administration of cloxacillin-loaded CS-NPs in the treatment of mastitis may improve cloxacillin therapeutic properties and could act as a potential alternative to the cloxacillin antibiotic for the treatment of bovine mastitis.
Indexed as
Identifiers
39753774What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.